Gumussoy Murat, Kucuk Ulku
1 Department of Otolaringology Head and Neck Surgery, University of Health Sciences, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
2 Department of Pathology, University of Health Sciences, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
Ann Otol Rhinol Laryngol. 2019 Oct;128(10):903-910. doi: 10.1177/0003489419848792. Epub 2019 May 9.
In laryngology practice, vocal fold leukoplakia is frequently evaluated by suspension laryngoscopy and biopsy examination upon the patient's complaints of hoarseness and dysphonia. The purpose of the present study is to investigate and analyze risk factors, diagnosis, treatment, and follow-up results of cases with Candida leukoplakia.
Retrospective case control study.
Tertiary medical center.
Patients with a diagnosis of vocal fold leukoplakia who underwent direct laryngoscopy and biopsy between 2007 and 2017 and diagnosed as candida or noncandida in their histopathology were assigned into 2 groups. Then they were compared in terms of their demographic characteristics, predisposing factors, diagnosis, treatment, and follow-up results.
Of the 289 vocal fold leukoplakia cases, 36 were candida, and 253 were noncandida. The mean age of the patients with Candida leukoplakia was 60.86 years. As for the age groups, the largest group (26.1%) was in the seventh decade ( < .001). The use of inhaled corticosteroids was a significant risk factor ( < .001). For their medical therapy, the patients were administered fluconazole 200 mg per day for 3 weeks, and the treatment yielded successful results in 91.66% of them. In 5 of the patients, candida leukoplakia and superficial epithelial dysplasia were observed, and no malignant transformation was observed during a mean follow-up of 28 ± 13 months.
Candidiasis causing vocal fold leukoplakia is rare, and we report the findings of the largest published case series to date. Eliminating predisposing factors and administrating oral fluconazole 200 mg for 3 weeks are sufficient for medical treatment.
在喉科学实践中,声带白斑常因患者声音嘶哑和发声困难的主诉而通过悬吊喉镜和活检检查进行评估。本研究的目的是调查和分析念珠菌性白斑病例的危险因素、诊断、治疗及随访结果。
回顾性病例对照研究。
三级医疗中心。
将2007年至2017年间接受直接喉镜检查和活检且组织病理学诊断为念珠菌性或非念珠菌性的声带白斑患者分为两组。然后比较两组患者的人口统计学特征、诱发因素、诊断、治疗及随访结果。
289例声带白斑病例中,36例为念珠菌性,253例为非念珠菌性。念珠菌性白斑患者的平均年龄为60.86岁。按年龄组划分,最大的一组(26.1%)为70岁年龄段(P<0.001)。吸入性糖皮质激素的使用是一个显著的危险因素(P<0.001)。在药物治疗方面,患者每天服用200毫克氟康唑,持续3周,91.66%的患者治疗取得成功。5例患者同时存在念珠菌性白斑和浅表上皮发育异常,在平均28±13个月的随访期间未观察到恶变。
引起声带白斑的念珠菌病较为罕见,我们报告了迄今为止已发表的最大病例系列的研究结果。消除诱发因素并口服200毫克氟康唑3周足以进行药物治疗。